EMA

Professional development Vacancies
EMA
Uppsala Monitoring Centre signal on VigiLyze: medicinal products containing risperidone and cerebrovascular disorders (stroke) in women

Uppsala Monitoring Centre signal on VigiLyze: medicinal products containing risperidone and cerebrovascular accidents (stroke) in women (signal in…

Read more
Overview of the recommendations adopted by the PRAC for medicinal products containing tumor necrosis factor alpha inhibitors: adalimumab; etanercept; golimumab; infliximab – Kaposi sarcoma

Overview of the recommendations adopted by the PRAC on signals discussed at the meeting of 6-9 July 2020, medicinal products containing…

Read more
Uppsala Monitoring Centre signal in VigiLyze: yellow fever vaccine and herpes zoster

(signal under investigation) This report contains 29 cases of herpes zoster, recorded on average 6 days after…

Read more
Final legally binding decision of the European Commission for EU countries on determining the DPD enzyme level before starting treatment with medicinal products containing fluorouracil, capecitabine, and tegafur

Final decision of the European Commission, adopted in July 2020, on mandatory testing of the DPD enzyme level before treatment with products based on fluorouracil, capecitabine, and tegafur. The document contains recommendations for patients and healthcare professionals and a list of the relevant medicinal products authorized in Ukraine. compiled automatically

Read more
Uppsala Monitoring Centre signal on VigiLyze: medicinal products containing methotrexate

(signal under investigation) Methotrexate is a drug developed as a structural analogue of folic acid. It blocks purine synthesis by inhibiting numerous regulatory…

Read more
Regarding amendments to the instructions for medical use of medicinal products containing macrogol (all molecular weights and combinations) for bowel preparation – ischemic colitis

Having considered the available evidence from reports in EudraVigilance and the literature, and taking into account the seriousness of the event, the PRAC committee agreed that…

Read more
Regarding amendments to the instructions for medical use of medicinal products belonging to hormone replacement therapy: tibolone – new information on a known risk of breast cancer

Tibolone was discussed at the PRAC meeting on 14-17 May 2020 as part of a signal on hormone replacement therapy (HRT). Translations of changes…

Read more
Regarding amendments to the instructions for medical use of medicinal products containing desogestrel – suppression of lactation

Having reviewed the cumulative review provided by the registration certificate holder for the medicinal product Cerazette, including the available clinical trial data, literature, and data from…

Read more
EMA starts review of Varilrix vaccine (live attenuated vaccine containing varicella zoster virus, OKA strain)

EMA starts a review of the Varilrix vaccine (live attenuated vaccine containing varicella zoster virus, OKA strain) EMA has started a review of the Varilrix vaccine,…

Read more
New measures to avoid errors with medicinal products containing leuprorelin in depot form

On May 14, 2020, the PRAC recommended measures to avoid errors in the preparation and administration of medicinal products containing leuprorelin…

Read more